OncoMatch/Clinical Trials/NCT06060782
Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
Is NCT06060782 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen for burkitt lymphoma.
Treatment: Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen — This study is an observational study on the efficacy and safety of auto-HSCT in adult patients with Burkitt lymphoma, lymphoblastic lymphoma, and acute lymphoblastic leukemia who received TCCA conditioning regimen. The study plans to include 28 patients who received the TCCA regimen for pre-transplantation pretreatment before auto-HSCT. Maintenance treatment will be carried out after transplantation for 1 year to observe the efficacy and safety.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: BCR fusion
PH+ALL patients
Required: BCR fusion negative
Ph-B-ALL patients
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: hematopoietic stem cell transplant — autologous
Patients receiving autologous hematopoietic stem cell transplantation (auto-HSCT)
Cannot have received: hematopoietic stem cell transplant
Received hematopoietic stem cell transplantation within the past 1 year
Lab requirements
Cardiac function
No active heart disease (uncontrolled/symptomatic angina, recent MI <6 months, arrhythmia requiring treatment or severe symptoms, uncontrolled/symptomatic CHF >NYHA class 2, ejection fraction below normal)
Active heart disease, defined as one or more of the following: uncontrolled or symptomatic angina; myocardial infarction less than 6 months; arrhythmia requiring drug treatment or severe symptoms; uncontrolled or symptomatic congestive heart failure (>NYHA class 2); ejection fraction is lower than the lower limit of the normal range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06060782 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hematopoietic stem cell transplant disqualifies patients from enrollment.
Does this trial require BCR?
Yes, BCR fusion is a required biomarker for enrollment.
Does this trial require BCR?
Yes, BCR fusion negative is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify